Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) is a clinical-stage gene editing company developing in vivo therapies for genetic and infectious diseases using its proprietary ARCUS platform. This Form 10-Q covers the quarterly period ended March 31, 2026. The company operates as a single segment focused on the discovery and development of therapies, with lead programs targeting chronic hepatitis B (PBGENE-HBV) and Duchenne muscular dystrophy (PBGENE-DMD).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $10.8 million | $0.03 million |
| Net Loss | $(18.4) million | $(20.6) million |
| Operating Loss | $(9.1) million | $(22.1) million |
| Research & Development Expenses | $13.1 million | $13.6 million |
| General & Administrative Expenses | $6.8 million | $8.6 million |
| Cash and Cash Equivalents | $99.4 million | $77.2 million |
| Restricted Cash | $26.5 million | $22.6 million |
| Total Debt (Loan Payable) | $22.4 million | N/A |
| Warrant Liability | $22.8 million | $15.7 million |
| Accumulated Deficit | $(546.6) million | $(503.0) million |
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased to $10.8 million from $29,000 in the prior year. This was driven by a $6.8 million milestone payment from TG Therapeutics (related to azer-cel) and $4.0 million from a legacy agriculture industry collaboration.
- Reduced Operating Loss: Operating loss improved significantly to $9.1 million from $22.1 million, primarily due to the revenue recognition and a $1.8 million decrease in G&A expenses.
- Non-Cash Fair Value Adjustments: The company recorded a $7.1 million non-cash loss on the change in fair value of warrant liabilities and a $3.0 million loss on changes in other fair value adjustments (Imugene shares), compared to a $0.8 million warrant loss and a $0.05 million gain in the prior year.
- Expense Management: R&D expenses decreased slightly ($0.5 million) due to the pause in the PBGENE-3243 program, offset by increased costs for PBGENE-DMD and PBGENE-HBV development.
Guidance, Outlook, and Risks
- Cash Runway: Management believes existing cash, cash equivalents, and the availability of its At-The-Market (ATM) facility are sufficient to fund operations through 2028.
- Clinical Progress:
- PBGENE-HBV: First-in-human trial (ELIMINATE-B) is ongoing; data presentation accepted for EASL Congress 2026. CTA approval received to expand into France and Romania.
- PBGENE-DMD: Received FDA Fast Track designation in March 2026. First clinical trial site activated in April 2026.
- PBGENE-3243: Development paused to prioritize lead programs.
- Key Risks:
- Liquidity: The company has incurred significant losses since inception and expects to continue doing so. It requires substantial additional funding to advance programs.
- Debt Covenants: The company must maintain a cash security account equal to the outstanding principal of its $22.5 million term loan ($22.5 million restricted cash).
- Regulatory & Development: Risks include the novel nature of ARCUS technology, potential clinical trial failures, and the rigorous regulatory landscape for gene editing.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the $10.8 million revenue, noting it is derived from one-time milestone payments rather than recurring product sales.
- Warrant Liability Volatility: Monitor the $22.8 million warrant liability, as mark-to-market adjustments significantly impact reported net loss without affecting cash flow.
- Cash Restrictions: Confirm that the $26.5 million in restricted cash is strictly tied to debt covenants and executive escrow arrangements, limiting immediate liquidity for operations.
- Program Prioritization: Assess the strategic impact of pausing the PBGENE-3243 program and the capital requirements for advancing PBGENE-HBV and PBGENE-DMD.
- Debt Servicing: Review the terms of the $22.5 million Banc of California term loan, including the 5.25% interest rate and the requirement to maintain collateral.